Core Insights - Edesa Biotech, Inc. has announced that its CEO, Dr. Par Nijhawan, will deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the company's Phase 3 study results for paridiprubart, an anti-TLR4 antibody for treating Acute Respiratory Distress Syndrome (ARDS) [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, with a clinical pipeline targeting Medical Dermatology and Respiratory conditions [6] - The company is developing paridiprubart (EB05) as a treatment for ARDS, a condition that leads to over three million ICU admissions globally each year [2][6] Clinical Study Details - The Phase 3 study of paridiprubart has reported results from an initial cohort of 104 patients requiring invasive mechanical ventilation, followed by expanded results from a total of 278 patients, indicating potential clinical benefits [2] - Dr. Ted Steiner, the principal investigator of the Phase 3 study, will present comprehensive results at the ATS 2026 International Conference on May 20, 2026 [4] Presentation Significance - Dr. Nijhawan expressed that being invited to lead the innovation showcase is a validation of the strength of the Phase 3 data and the potential of paridiprubart to transform ARDS treatment, which currently has limited effective options [3] Therapeutic Mechanism - Paridiprubart represents a new class of host-directed therapeutics designed to modulate the immune response against various public health threats, including infectious diseases and other emergencies [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Delaware 47-2641188 (State or other jurisdiction of incorporation or organization) 983 University Avenue, Bldg. B Los Gatos, California 95032 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2641188 (State or other jurisdiction of incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2641188 (State or other jurisdiction of incorporation or or ...

Washington, D.C. 20549 FORM 10-K (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38630 Aridis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-2641188 (State or other jurisdi ...